SynCo Bio commences release of drug products after expansion of Class A zone

Aug 4 2011

SynCo Bio Partners B.V., one of the leading GMP contract manufacturers of biopharmaceuticals today announced that its aseptic filling facility is again fully operational and SynCo has produced and released the first drug product batches for its clients after the expansion of its Class A zone.  

The expansion of the Class A zone is an important milestone in SynCo's strategy in supporting its clients with new product launches in the US and the rest of the world.  SynCo's aseptic filling facility is able to fill and lyophilize a wide range of biopharmaceuticals which include proteins, monoclonal antibodies, polysaccharides, nucleic acids, aluminium containing vaccines, RNA and live biotherapeutics for clinical and market supply.

Announcing this upgrade, Pierre Warffemius, CEO of SynCo Bio Partners said:

"The expansion of the Class A zone is an excellent addition to SynCo Bio Partners' already state-of-the-art contract manufacturing facility in Amsterdam. SynCo is one of the few biopharmaceutical CMOs in the world with a recognized track record in both clinical and commercial manufacturing of both bulk drug substance and drug product and continuously invests in its facilities to achieve its goal: Trust us to make it right."